Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilvegostomig in advanced gastric cancer
NCT07788664Phase 2Not yet recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2026
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
A Phase 2 trial of rilvegostomig in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Vall d'Hebron Institute of Oncology. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
rilvegostomig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07788664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788664.